Profilaxis de reinfección por el virus de la hepatitis B postrasplante hepático
| Autor: | F. García Pajares, J M Prada Lobato, M. A. Catalá Pindado, S. Garrido López |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Pharmacology
Hepatitis B virus medicine.medical_specialty business.industry medicine.medical_treatment Lamivudine Hepatitis B Liver transplantation medicine.disease medicine.disease_cause Gastroenterology law.invention Transplantation Clinical trial Randomized controlled trial law Internal medicine Immunology medicine Adefovir business medicine.drug |
| Zdroj: | Farmacia Hospitalaria. 31:30-37 |
| ISSN: | 1130-6343 |
| DOI: | 10.1016/s1130-6343(07)75708-2 |
| Popis: | Objective: To review the prophylaxis against post-liver transplantation hepatitis B reinfection with anti-hepatitis B immunoglobulin and nucleoside analogues. Method: A bibliographic search was carried out using Pubmed, entering the following key words: hepatitis B and liver transplantation and (hepatitis B hyperimmune globulin and lamivudine and adefovir dipivoxil) up to June 2006. The initial search was filtered using the terms clinical trial, randomized clinical trial and review. The data contained in selected studies were reviewed. Results: A total of 53 works were found. Prophylaxis with anti-HB immunoglobulin and lamivudine is the best strategy for avoiding recurrence of the hepatitis B virus in patients undergoing hepatic transplants; achieving very low reinfection rates (0-10%) with follow up periods of between 1-5 years. There is a great degree of variability (dose, duration and method of HBIg administration) in the prophylactic protocols reviewed. The use of low doses of anti-HB immunoglobulin (administered intravenously followed by intramuscular administration, or administered intramuscularly from the anhepatic stage), and lamivudine in patients who receive transplants with a low risk of recurrence, shows prophylactic efficacy comparable to the use of high doses of anti- HB immunoglobulin. Furthermore, it implies a considerable reduction in costs. Conclusions: The availability of suitably designed clinical trials is required to design a more cost-effective protocol and reduce variability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|